메뉴 건너뛰기




Volumn 26, Issue 5, 2015, Pages 914-920

Effect of brca1 and xpg mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: Exploratory analysis of the phase 3 ova-301 study

Author keywords

BRCA1; Pegylated liposomal doxorubicin; Recurrent ovarian cancer; Trabectedin; XPG

Indexed keywords

BRCA1 PROTEIN; DNA; DOXORUBICIN; NUCLEIC ACID BINDING PROTEIN; PLATINUM DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; XPG PROTEIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BRCA1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; MACROGOL DERIVATIVE; NUCLEAR PROTEIN; TETRAHYDROISOQUINOLINE DERIVATIVE; TRANSCRIPTION FACTOR;

EID: 84929073473     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv071     Document Type: Article
Times cited : (62)

References (17)
  • 2
    • 84872659173 scopus 로고    scopus 로고
    • Patient-derived breast tumor xenografts facilitating personalized cancer therapy
    • Landis MD, Lehmann BD, Pietenpol JA et al. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 2013; 15: 201.
    • (2013) Breast Cancer Res , vol.15 , pp. 201
    • Landis, M.D.1    Lehmann, B.D.2    Pietenpol, J.A.3
  • 3
    • 84929074678 scopus 로고    scopus 로고
    • (10 December 2014, date last accessed)
    • Product monograph [database on the Internet] 2010. http://hemonc.org/docs/packageinsert/trabectedin.pdf (10 December 2014, date last accessed).
    • (2010) Product monograph [database on the Internet]
  • 4
    • 20144388299 scopus 로고    scopus 로고
    • Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production
    • Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 2964-2971.
    • (2005) Cancer Res , vol.65 , pp. 2964-2971
    • Allavena, P.1    Signorelli, M.2    Chieppa, M.3
  • 5
    • 84873597334 scopus 로고    scopus 로고
    • Role of macrophage targeting in the antitumor activity of trabectedin
    • Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23: 249-262.
    • (2013) Cancer Cell , vol.23 , pp. 249-262
    • Germano, G.1    Frapolli, R.2    Belgiovine, C.3
  • 6
    • 77955491837 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
    • Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
    • (2010) J Clin Oncol , vol.28 , pp. 3107-3114
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3
  • 7
    • 84867525162 scopus 로고    scopus 로고
    • Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer
    • Monk BJ, Dalton H, Benjamin I et al. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012; 18(25): 3754-3769.
    • (2012) Curr Pharm Des , vol.18 , Issue.25 , pp. 3754-3769
    • Monk, B.J.1    Dalton, H.2    Benjamin, I.3
  • 8
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 9
    • 84929075267 scopus 로고    scopus 로고
    • Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial
    • Lorusso D FG, Pignata S, Sorio R et al. Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. J Clin Oncol 2014; 32: 5s (suppl; abstr 5530).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Lorusso, D.F.G.1    Pignata, S.2    Sorio, R.3
  • 10
    • 0033558282 scopus 로고    scopus 로고
    • Survival in familial, brca1-associated, and brca2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) familial ovarian cancer study group
    • Pharoah PD, Easton DF, Stockton DL et al. Survival in familial, brca1-associated, and brca2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) familial ovarian cancer study group. Cancer Res 1999; 59: 868-871.
    • (1999) Cancer Res , vol.59 , pp. 868-871
    • Pharoah, P.D.1    Easton, D.F.2    Stockton, D.L.3
  • 11
    • 33847167062 scopus 로고    scopus 로고
    • Improved survival in brca2 carriers with ovarian cancer
    • Pal T, Permuth-Wey J, Kapoor R et al. Improved survival in brca2 carriers with ovarian cancer. Fam Cancer 2007; 6: 113-119.
    • (2007) Fam Cancer , vol.6 , pp. 113-119
    • Pal, T.1    Permuth-Wey, J.2    Kapoor, R.3
  • 12
    • 57149093237 scopus 로고    scopus 로고
    • 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with brca1 and brca2 mutations
    • Tan DS, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with brca1 and brca2 mutations. J Clin Oncol 2008; 26: 5530-5536.
    • (2008) J Clin Oncol , vol.26 , pp. 5530-5536
    • Tan, D.S.1    Rothermundt, C.2    Thomas, K.3
  • 13
    • 84876415689 scopus 로고    scopus 로고
    • Brca1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study
    • Lesnock JL, Darcy KM, Tian C et al. Brca1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer 2013; 108: 1231-1237.
    • (2013) Br J Cancer , vol.108 , pp. 1231-1237
    • Lesnock, J.L.1    Darcy, K.M.2    Tian, C.3
  • 14
    • 84859523588 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    • Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
    • (2012) N Engl J Med , vol.366 , pp. 1382-1392
    • Ledermann, J.1    Harter, P.2    Gourley, C.3
  • 15
    • 84856158117 scopus 로고    scopus 로고
    • Association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer
    • Bolton KL, Chenevix-Trench G, Goh C et al. Association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307: 382-390.
    • (2012) JAMA , vol.307 , pp. 382-390
    • Bolton, K.L.1    Chenevix-Trench, G.2    Goh, C.3
  • 16
    • 84872517041 scopus 로고    scopus 로고
    • Long-term ovarian cancer survival associated with mutation in brca1 or brca2
    • McLaughlin JR, Rosen B, Moody J et al. Long-term ovarian cancer survival associated with mutation in brca1 or brca2. J Natl Cancer Inst 2013; 105: 141-148.
    • (2013) J Natl Cancer Inst , vol.105 , pp. 141-148
    • McLaughlin, J.R.1    Rosen, B.2    Moody, J.3
  • 17
    • 41549100818 scopus 로고    scopus 로고
    • DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (et-743)
    • Schoffski PCP, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (et-743). J Clin Oncol 2006; 24: 525s (suppl; abstr 9522).
    • (2006) J Clin Oncol , vol.24 , pp. 525s
    • Schoffski, P.C.P.1    Taron, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.